Cobimetinib Plus Vemurafenib: A Review in BRAFV600 Mutation-Positive Unresectable or Metastatic Melanoma

被引：13

作者：

Keating, Gillian M. ^{[1
]}

机构：

[1] Springer, Private Bag 65901, Auckland 0754, New Zealand

来源：

DRUGS | 2016年 / 76卷 / 05期

关键词：

OPEN-LABEL; MEK INHIBITOR; TARGETED THERAPY; BRAF INHIBITION; RESISTANCE; PEMBROLIZUMAB; MECHANISMS; IPILIMUMAB; SURVIVAL; PHARMACOKINETICS;

D O I：

10.1007/s40265-016-0562-7

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The MEK inhibitor cobimetinib (Cotellic (R)) is indicated for the treatment of patients with BRAF(V600) mutation-positive unresectable or metastatic melanoma, in combination with the BRAF inhibitor vemurafenib (Zelboraf (R)). In the pivotal coBRIM trial, previously untreated patients with BRAF(V600) mutation-positive unresectable, stage IIIC or stage IV melanoma received cobimetinib 60 mg once daily for the first 21 days of each 28-day cycle plus vemurafenib 960 mg twice daily or vemurafenib alone. Compared with vemurafenib alone, cobimetinib plus vemurafenib significantly prolonged progression-free survival (primary endpoint) and was associated with a significantly higher overall response rate and significantly prolonged overall survival. Cobimetinib plus vemurafenib had a manageable tolerability profile. In conclusion, cobimetinib plus vemurafenib is a valuable option for use in BRAF(V600) mutation-positive unresectable or metastatic melanoma.

引用

页码：605 / 615

页数：11

共 68 条

[1] Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks [J].

Anforth, R. ;

Carlos, G. ;

Clements, A. ;

Kefford, R. ;

Fernandez-Penas, P. .

BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (01) :239-243

[2]

[Anonymous], 2015, NCCN clinical practice guidelines in oncology: Prostate cancer

[3] Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway [J].

Atefi, Mohammad ;

von Euw, Erika ;

Attar, Narsis ;

Ng, Charles ;

Chu, Connie ;

Guo, Deliang ;

Nazarian, Ramin ;

Chmielowski, Bartosz ;

Glaspy, John A. ;

Comin-Anduix, Begonya ;

Mischel, Paul S. ;

Lo, Roger S. ;

Ribas, Antoni .

PLOS ONE, 2011, 6 (12)

[4]

Atkinson V, 2015, SOC MEL RES 2015 C

[5] Vemurafenib Potently Induces Endoplasmic Reticulum Stress-Mediated Apoptosis in BRAFV600E Melanoma Cells [J].

Beck, Daniela ;

Niessner, Heike ;

Smalley, Keiran S. M. ;

Flaherty, Keith ;

Paraiso, Kim H. T. ;

Busch, Christian ;

Sinnberg, Tobias ;

Vasseur, Sophie ;

Iovanna, Juan Lucio ;

Driessen, Stefan ;

Stork, Bjoern ;

Wesselborg, Sebastian ;

Schaller, Martin ;

Biedermann, Tilo ;

Bauer, Juergen ;

Lasithiotakis, Konstantinos ;

Weide, Benjamin ;

Eberle, Juergen ;

Schittek, Birgit ;

Schadendorf, Dirk ;

Garbe, Claus ;

Kulms, Dagmar ;

Meier, Friedegund .

SCIENCE SIGNALING, 2013, 6 (260)

[6]

Bristol-Myers Squibb Company, 2016, NIV OPD INJ INT US U

[7] Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [J].

Chapman, Paul B. ;

Hauschild, Axel ;

Robert, Caroline ;

Haanen, John B. ;

Ascierto, Paolo ;

Larkin, James ;

Dummer, Reinhard ;

Garbe, Claus ;

Testori, Alessandro ;

Maio, Michele ;

Hogg, David ;

Lorigan, Paul ;

Lebbe, Celeste ;

Jouary, Thomas ;

Schadendorf, Dirk ;

Ribas, Antoni ;

O'Day, Steven J. ;

Sosman, Jeffrey A. ;

Kirkwood, John M. ;

Eggermont, Alexander M. M. ;

Dreno, Brigitte ;

Nolop, Keith ;

Li, Jiang ;

Nelson, Betty ;

Hou, Jeannie ;

Lee, Richard J. ;

Flaherty, Keith T. ;

McArthur, Grant A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2507-2516

[8] Role of P-Glycoprotein on the Brain Penetration and Brain Pharmacodynamic Activity of the MEK Inhibitor Cobimetinib [J].

Choo, Edna F. ;

Ly, Justin ;

Chan, Jocelyn ;

Shahidi-Latham, Sheerin K. ;

Messick, Kirsten ;

Plise, Emile ;

Quiason, Cristine M. ;

Yang, Lulu .

MOLECULAR PHARMACEUTICS, 2014, 11 (11) :4199-4207

[9] Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance [J].

Das Thakur, Meghna ;

Salangsang, Fernando ;

Landman, Allison S. ;

Sellers, William R. ;

Pryer, Nancy K. ;

Levesque, Mitchell P. ;

Dummer, Reinhard ;

McMahon, Martin ;

Stuart, Darrin D. .

NATURE, 2013, 494 (7436) :251-255

[10]

De La Cruz-Merino L, 2015, J CLIN ONCOL S1, V33

← 1 2 3 4 5 6 7 →